Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
62 hedge funds and large institutions have $14.2M invested in Astria Therapeutics in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 14 closing their positions.
80% more call options, than puts
Call options by funds: $397K | Put options by funds: $220K
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
22% more funds holding
Funds holding: 51 → 62 (+11)
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
1.44% less ownership
Funds ownership: 7.2% → 5.77% (-1.4%)
72% less capital invested
Capital invested by funds: $51M → $14.2M (-$36.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.93M |
| 2 |
Morgan Stanley
New York
|
+$1.85M |
| 3 |
EP
Eversept Partners
New York
|
+$1.55M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$558K |
| 5 |
State Street
Boston,
Massachusetts
|
+$369K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$18.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.29M |
| 3 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$1.77M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$901K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$601K |
ATXS Hedge Fund Activity: Q4 2020 in Review
62 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2020, worth a combined $14.2M — down 72% from $51M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ATXS positions and 14 closed out — a net gain of 11 holders — while 16 added to existing stakes and 14 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $1.93M. The largest seller was Federated Hermes, exiting entirely with an estimated $18.9M sold.
- 62 institutional investors held Astria Therapeutics (ATXS) as of Q4 2020, up from 51 in Q3 2020.
- Funds reported $14.2M of Astria Therapeutics stock for Q4 2020, down 72% quarter-over-quarter.
- 25 funds opened new Astria Therapeutics positions in Q4 2020 and 14 closed out, a net change of +11 holders.
- The largest Astria Therapeutics buyer in Q4 2020 was Ikarian Capital, an estimated $1.93M added.
- The largest Astria Therapeutics seller in Q4 2020 was Federated Hermes, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2020.